Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Janice M MehnertEmily BergslandBert H O'NeilArmando SantoroJan H M SchellensRoger B CohenToshihiko DoiPatrick A OttMichael J PishvaianIgor PuzanovKyaw L AungChiun HsuChristophe Le TourneauAntoine HollebecqueElena ÉlezKenji TamuraMarlena GouldPing YangKaren SteinSarina A Piha-PaulPublished in: Cancer (2020)
Pembrolizumab demonstrated antitumor activity in a subset of patients with NETs and was well-tolerated.